Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01150045 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | completed | Phase 3 | 2,527 | Alliance for Clinical Trials in OncologyOTHER | 3 | May 19, 2026 | clinicaltrials |
| NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC(DUBLIN-3) | completed | Phase 3 | 559 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 3 |
| May 19, 2026 |
| clinicaltrials |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 174 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT02514278 | Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy(GRECCAR12) | completed | Phase 3 | 218 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03891914 | Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma(MYELOCHOL) | completed | Phase 3 | 20 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04835142 | Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC | completed | Phase 3 | 688 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | completed | Phase 3 | 343 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | May 8, 2026 | clinicaltrials |
| NCT02973386 | Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients | completed | Phase 3 | 294 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT03784014 | Molecular Profiling of Advanced Soft-tissue Sarcomas(MULTISARC) | completed | Phase 3 | 603 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Apr 29, 2026 | clinicaltrials |
| NCT01744249 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | completed | Phase 2 / Phase 3 | 256 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Apr 28, 2026 | clinicaltrials |
| NCT02633202 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | completed | Phase 3 | 338 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03593018 | Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | completed | Phase 3 | 86 | The Lymphoma Academic Research OrganisationOTHER | 5 | Apr 23, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT02584985 | Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer(ETAP) | completed | Phase 3 | 226 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix(BEATcc) | completed | Phase 3 | 410 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 8 | Apr 21, 2026 | clinicaltrials |
| NCT03710876 | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma(INFINITE) | completed | Phase 3 | 53 | Ferring Ventures LimitedINDUSTRY | 9 | Apr 21, 2026 | clinicaltrials |
| NCT04732598 | A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer(AMBITION) | completed | Phase 3 | 281 | Japanese Foundation for Cancer ResearchOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment(TORCHLIGHT) | completed | Phase 3 | 531 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
| NCT04924062 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | completed | Phase 3 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02311959 | Therapeutic Nipple Sparing Mastectomy.(MAPAM-01) | completed | Phase 3 | 450 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02771405 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC(FRI-STC) | completed | Phase 3 | 150 | National Hepatology & Tropical Medicine Research InstituteOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO](ENGOT-EN5) | completed | Phase 3 | 263 | Karyopharm Therapeutics IncINDUSTRY | 10 | Apr 13, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL(DEB) | completed | Phase 3 | 423 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00430365 | Maintenance Therapy Using Lenalidomide in Myeloma(IFM2005-02) | completed | Phase 3 | 614 | University Hospital, ToulouseOTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT01191060 | Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years(IFM/DFCI2009) | completed | Phase 3 | 700 | University Hospital, ToulouseOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT00116454 | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis(Lipiocis) | completed | Phase 3 | 73 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT00931645 | Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia(Auto-LLC 2001) | completed | Phase 3 | 241 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02044354 | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer(CABA-DOC) | completed | Phase 3 | 195 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02435953 | TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma(TORCH) | completed | Phase 3 | 241 | Ming ZhaoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT03401060 | Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis(DenosuMast) | completed | Phase 3 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT00003140 | Letrozole After Tamoxifen in Treating Women With Breast Cancer | completed | Phase 3 | 5,187 | NCIC Clinical Trials GroupNETWORK | 2 | Mar 27, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis(TRANSFORM-1) | completed | Phase 3 | 252 | AbbVieINDUSTRY | 25 | Mar 23, 2026 | clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2026source: clinicaltrials